

# Cryoablation of atrial flutter

<b>Submission date</b> 23/03/2012	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 03/04/2012	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 18/09/2014	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Atrial flutter is an abnormality in the beating of the heart, also known as arrhythmias. This arrhythmia can be the cause of stroke, heart failure and eventually death. This heart condition is successfully treatable today with catheter ablation, which destroys a small area of heart tissue that is causing rapid and irregular heartbeats. The aim of this study was to compare two commonly used catheter ablation technologies, namely radiofrequency (burning of the tissue), which is the standard treatment, and cryoablation (freezing of the tissue), which is the alternative treatment.

### Who can participate?

All patients regardless of age and gender with clear atrial flutter symptoms can participate in this study.

### What does the study involve?

In order to evaluate heart function, patients undergo a clinical examination, ECG recording and echocardiography. Patients will then be randomly allocated to be treated with either radiofrequency or cryoablation. Six months after treatment all patients will be followed up with an out-patient visit and an ECG recording.

### What are the possible benefits and risks of participating?

The possible benefits of participating are that cryoablation is practically painless and equally effective to standard treatment (radiofrequency). No risks have been shown in the clinical studies published so far.

### Where is the study run from?

The study is run from Karolinska University Hospital, Stockholm, Sweden.

### When is the study starting and how long is it expected to run for?

The study ran from January 2007 to November 2010.

### Who is funding the study?

Financial support was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and the Karolinska Institute (Sweden).

Who is the main contact?  
Dr Hamid Bastani  
Karolinska University Hospital, Stockholm, Sweden

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Mats Jensen-Urstad

**Contact details**  
Department of Cardiology  
Karolinska Institute  
Karolinska University Hospital  
Stockholm  
Sweden  
14186  
mats.jensen-urstad@karolinska.se

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N/A

## Study information

**Scientific Title**  
Cryothermal versus Radiofrequency Ablation as atrial Flutter Therapy: a randomized comparison

**Acronym**  
CRAFT

**Study objectives**  
Catheter ablation with cryothermal energy is non-inferior to ablation with radiofrequency energy for the treatment of cavotricuspid isthmus (CTI)-dependent atrial flutter (AFL)

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**  
Regional Ethical Review Board, Stockholm, 2006, ref: 1006-31

**Study design**

Prospective single-blinded randomized controlled single-centre trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Atrial flutter

**Interventions**

Cryo group:

Cryo was delivered with the use of a steerable 9F, 8-mm-tip catheter (Freezor MAX, CryoCath, Quebec, Canada), which was positioned on the TV annulus. Cryoablation was then performed using a sequential application technique point-by-point from the TV annulus to the inferior vena cava (IVC).

RF group:

RF was performed using a 7F 3.5-mm open-irrigated-tip catheter (Biosense-Webster Inc., Diamond Bar, CA. USA) to create an ablation line between the tricuspid valve and the IVC.

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome measure**

Clinical success defined as the freedom from atrial flutter evaluated at the 6-month follow-up.

**Secondary outcome measures**

1. Acute ablation success defined as bidirectional CTI-block safety assessed by the rate of periprocedural complications, procedure and fluoroscopy times and the level of pain experienced by the patient during the ablation procedure
2. To compare the utility of non-fluoroscopic mapping systems (Ensite NavX) with conventional mapping all patients were also randomized to either fluoroscopy only or Ensite NavX and fluoroscopy

**Overall study start date**

01/01/2007

**Completion date**

30/11/2010

## Eligibility

**Key inclusion criteria**

1. Consecutive patients referred to our institution for ablation therapy of ECG-documented typical CTI-dependent AFL
2. Patients above the age of 18 with symptomatic CTI-dependent AFL documented on a 12-lead ECG with typical ECG appearance of negative saw tooth waves in the inferior limb leads and positive deflections in V1 or positive saw tooth waves in the inferior limb leads and negative deflections in V1
3. Patients with a history of atrial fibrillation included if they had predominant atrial flutter under chronic treatment with class I or III antiarrhythmic agents

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

150

**Key exclusion criteria**

1. Prior ablation for AFL
2. Atrial flutter related to recently undergone surgery, hyperthyroidism or other severe disease
3. Inability to adhere to the study protocol
4. Pregnancy
5. Predominant atrial fibrillation
6. Contraindication to warfarin

**Date of first enrolment**

01/01/2007

**Date of final enrolment**

30/11/2010

## Locations

**Countries of recruitment**

Sweden

**Study participating centre**  
**Department of Cardiology**  
Stockholm  
Sweden  
14186

## **Sponsor information**

**Organisation**  
Karolinska University Hospital (Sweden)

**Sponsor details**  
Department of Cardiology  
Stockholm  
Sweden  
141 86  
+46 8 585 800 00  
mats.jensen-urstad@karolinska.se

**Sponsor type**  
University/education

**Website**  
<http://www.karolinska.se/en/>

**ROR**  
<https://ror.org/00m8d6786>

## **Funder(s)**

**Funder type**  
Government

**Funder Name**  
Stockholm County Council (Sweden)

**Alternative Name(s)**  
Stockholm County Council

**Funding Body Type**  
Government organisation

**Funding Body Subtype**

Local government

**Location**

Sweden

**Funder Name**

Karolinska Institute (Sweden)

## **Results and Publications**

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration